- Home
- ALXO vs IAE Comparison
ALXO vs IAE Comparison
Compare ALXO & IAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALXO
- IAE
- Stock Information
- Founded
- ALXO 2015
- IAE 2007
- Country
- ALXO United States
- IAE United States
- Employees
- ALXO N/A
- IAE N/A
- Industry
- ALXO Biotechnology: Pharmaceutical Preparations
- IAE Trusts Except Educational Religious and Charitable
- Sector
- ALXO Health Care
- IAE Finance
- Exchange
- ALXO Nasdaq
- IAE Nasdaq
- Market Cap
- ALXO 76.5M
- IAE 68.1M
- IPO Year
- ALXO 2020
- IAE N/A
- Fundamental
- Price
- ALXO $1.74
- IAE $6.11
- Analyst Decision
- ALXO Buy
- IAE
- Analyst Count
- ALXO 6
- IAE 0
- Target Price
- ALXO $11.00
- IAE N/A
- AVG Volume (30 Days)
- ALXO 1.1M
- IAE 46.3K
- Earning Date
- ALXO 03-06-2025
- IAE 01-01-0001
- Dividend Yield
- ALXO N/A
- IAE 10.21%
- EPS Growth
- ALXO N/A
- IAE N/A
- EPS
- ALXO N/A
- IAE N/A
- Revenue
- ALXO N/A
- IAE N/A
- Revenue This Year
- ALXO N/A
- IAE N/A
- Revenue Next Year
- ALXO N/A
- IAE N/A
- P/E Ratio
- ALXO N/A
- IAE N/A
- Revenue Growth
- ALXO N/A
- IAE N/A
- 52 Week Low
- ALXO $1.19
- IAE $5.31
- 52 Week High
- ALXO $17.83
- IAE $6.45
- Technical
- Relative Strength Index (RSI)
- ALXO 53.13
- IAE 49.07
- Support Level
- ALXO $1.56
- IAE $5.94
- Resistance Level
- ALXO $1.94
- IAE $6.13
- Average True Range (ATR)
- ALXO 0.16
- IAE 0.07
- MACD
- ALXO -0.01
- IAE 0.01
- Stochastic Oscillator
- ALXO 50.00
- IAE 62.96
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
About IAE Voya Asia Pacific High Dividend Equity Income Fund ING Asia Pacific High Dividend Equity Income Fund of Beneficial Interest
Voya Asia Pacific High Dividend Equity Income Fund is a United States-based diversified, closed-end fund.The investment objective of the fund is to provide a total return through a combination of current income, capital gains, and capital appreciation. To achieve this objective, under normal market conditions, the fund invests in a portfolio of dividend-yielding equity securities of companies located in the Asia Pacific region.